Ironwood Pharmaceuticals Stock News

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Matt Roache - Director, Investor Relations Tom McCourt - Chief Executive Offi

Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines

Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates.

Ironwood (IRWD) delivered earnings and revenue surprises of -22.22% and 2.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Upgrades For United Airlines Holdings Inc (NASDAQ:UAL), Argus Research upgraded the previous rating of Hold to Buy. For the first quarter, United Airlines Holdings had an EPS of $4.24, compared to yea

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1. Analyst Chris Howerton thinks Ardelyx "s

Ardelyx Inc (NASDAQ: ARDX ) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1 . Analyst Chris Howerton thinks Ardelyx "stands out" given that the Company has an approved IBS-C product, Isbrela, that will launch in April and whose commercial opportunity is validated by Linzess and Trulance. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD ) and AbbVie Inc''s (NYSE: ABBV ) Linzess achieved $1 billion in sales in 2021, while Salix Pharmaceuticals'' Trulance achieved … Full story available on Benzinga.com

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will be presenting at the following investor conferences: Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET Barclays Global Healthcare Conference on Tuesday, March 15, 2022 at 3:20 p.m. ET A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at www.ironwoodpharm

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will be presenting at the following investor conferences: Cowen

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates.